Sim Megan B, Rassekh Shahrad Rod
Department of Paediatrics, Division of Paediatric Hematology/Oncology/BMT, University of British Columbia, Vancouver, Canada.
Pediatr Nephrol. 2025 Jul 7. doi: 10.1007/s00467-025-06852-9.
Children with cancer have had significant improvements in cure rates over the last few decades through advancements in surgery, chemotherapy, and radiation therapy. However, survivors have been left with long-term adverse effects of therapy, including significant nephrotoxicity. With advancement in genomic sequencing and novel therapeutics, there has been a recent shift towards the incorporation of targeted therapies and immunotherapy to improve cure rates and reduce long-term sequelae in survivors. However, these new therapies are not without their own toxicities, and with more widespread use of these agents, paediatric oncologists and nephrologists need to be aware of the short- and long-term impact of these treatments on children with cancer. This review highlights some of the emerging knowledge regarding the impact of these novel therapeutics on the kidneys.
在过去几十年里，通过手术、化疗和放疗技术的进步，癌症患儿的治愈率有了显著提高。然而，幸存者却承受着治疗带来的长期不良影响，包括严重的肾毒性。随着基因组测序和新型疗法的发展，最近出现了向采用靶向治疗和免疫治疗的转变，以提高治愈率并减少幸存者的长期后遗症。然而，这些新疗法也有其自身的毒性，随着这些药物的更广泛使用，儿科肿瘤学家和肾病学家需要意识到这些治疗对癌症患儿的短期和长期影响。这篇综述重点介绍了一些关于这些新型疗法对肾脏影响的新认识。
